Antisense Therapeutics, Tianjin International deal
Antisense partnered with the academy to form a JV in Hong Kong to develop Antisense's ATL1102. Antisense will own a 49% stake and provide the JV with licenses to ATL1102 IP, while the academy will own a 51% stake and fund all development activities undertaken by the JV. The partners will share income from commercialization of ATL1102, with the academy responsible for commercialization in China and Hong Kong and Antisense responsible elsewhere. Antisense will be entitled to 20-50% of income derived in Hong Kong and China and 65-90% of income from the rest of the world, depending on the academy's level of investment in developing ATL1102. The academy will receive the remaining percent of profits. The JV will begin development activities in September, with an initial focus on evaluating injectable ATL1102 in a chronic toxicology study to support a Phase IIb study in patients with multiple sclerosis (MS). Other proposed activities for the JV include a Phase I trial of ATL1102 as a mobilization agent for stem cell transplantation and a Phase II trial of ATL1102 to treat asthma. ...